Regulated Information - Denominator

See the article here:
Information on the Total Number of Voting Rights (Denominator) following Conversion Notice from ATLA

HOUSTON, March 24, 2023 (GLOBE NEWSWIRE) -- Bio-Path Holdings, Inc. (NASDAQ: BPTH), a biotechnology company leveraging its proprietary DNAbilize® antisense RNAi nanoparticle technology to develop a portfolio of targeted nucleic acid cancer drugs, today announced that it will host a live conference call and audio webcast on Friday, March 31, 2023 at 8:30 a.m. ET to report financial results for the fourth quarter and full year ended December 31, 2022 and to provide a business overview.

Read the original:
Bio-Path Holdings to Announce Fourth Quarter and Full Year 2022 Financial Results on March 31, 2023

First TIL Therapy BLA Submission to U.S. Food and Drug Administration First TIL Therapy BLA Submission to U.S. Food and Drug Administration

See the original post here:
Iovance Biotherapeutics Completes Biologics License Application (BLA) Submission for Lifileucel in Advanced Melanoma

Conference call to be held on Thursday, March 30 at 8:30 a.m. ET Conference call to be held on Thursday, March 30 at 8:30 a.m. ET

See the article here:
Theriva Biologics to Reschedule Conference Call and Webcast to Discuss Fourth Quarter and Full-Year 2022 Operational Highlights and Financial Results

Conference Call to be held Friday, March 31, at 9:00am Eastern Time Conference Call to be held Friday, March 31, at 9:00am Eastern Time

Read more here:
Alimera Sciences to Report Fourth Quarter and Full Year 2022 Financial Results on Friday, March 31, 2023, and Provide Corporate Update

Montrouge, France, March 24, 2023

Read the rest here:
Ordinary and Extraordinary General Meeting of April 12, 2023

VOR BIOPHARMA INC. Management's Discussion and Analysis of Financial Condition and Results of Operations (form 10-K)  Marketscreener.com

Read the rest here:
VOR BIOPHARMA INC. Management's Discussion and Analysis of Financial Condition and Results of Operations (form 10-K) - Marketscreener.com

MAGENTA THERAPEUTICS, INC. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS (form 10-K)  Marketscreener.com

Read the original post:
MAGENTA THERAPEUTICS, INC. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS (form 10-K) - Marketscreener.com

BioRestorative Therapies to Seek FDA Approval to Expand the Clinical Application of BRTX-100  Marketscreener.com

Read more:
BioRestorative Therapies to Seek FDA Approval to Expand the Clinical Application of BRTX-100 - Marketscreener.com

BioSenic delivers a new post-hoc analysis of its Phase III JTA-004 trial on knee osteo-arthritis with positive action on the most severely affected patient population  Marketscreener.com

Visit link:
BioSenic delivers a new post-hoc analysis of its Phase III JTA-004 trial on knee osteo-arthritis with positive action on the most severely affected...

Regenerative Therapies Market is Set to Grow at a CAGR of 8.7% by 2033, Propelled by Advancements in  EIN News

Read the original post:
Regenerative Therapies Market is Set to Grow at a CAGR of 8.7% by 2033, Propelled by Advancements in - EIN News

Company to host conference call March 16, 2023, at 4:30 PM EDT Company to host conference call March 16, 2023, at 4:30 PM EDT

More here:
Achieve Life Sciences Reports Financial Results for Fourth Quarter and Year-End 2022 and Provides Corporate Update

Announced SC291 IND clearance with goal to report initial clinical data this year

Originally posted here:
Sana Biotechnology Reports Fourth Quarter and Full Year 2022 Financial Results and Business Updates

Management to host conference call on Wednesday, March 22 at 4:30 p.m. ET Management to host conference call on Wednesday, March 22 at 4:30 p.m. ET

See more here:
Rani Therapeutics to Report Fourth Quarter and Full Year 2022 Financial Results and Business Updates

Initial Phase 1b data for three ongoing clinical trials expected in second half of 2023: ORIC-533 in multiple myeloma, ORIC-114 in EGFR/HER2-mutated cancers, and ORIC-944 in prostate cancer

Read more:
ORIC Pharmaceuticals Reports Fourth Quarter and Full Year 2022 Financial Results and Operational Updates

CHATHAM, N.J., March 16, 2023 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP), a clinical-stage biopharmaceutical company, today announced that Herbert Harris, M.D., Ph.D., Executive Vice President, Translational Medicine of Tonix Pharmaceuticals, will deliver a presentation at the Rare Disease Innovation and Partnership Summit, which will be held as a hybrid event in Philadelphia, Pa., March 21 - March 23, 2023. A copy of the Company’s presentation will be available under the Scientific Presentations tab of the Tonix website at www.tonixpharma.com following the conference. Additional information can be found on the Rare Disease Innovation and Partnership Summit website here.

Read the original:
Tonix Pharmaceuticals Announces Presentation at the Rare Disease Innovation and Partnership Summit

Management to host investor conference call and webcast at 4:30pm ET on that day Management to host investor conference call and webcast at 4:30pm ET on that day

Read more here:
MedAvail to Report Fourth Quarter and Full Year 2022 Financial Results on March 30

See the original post:
Press Release: Sanofi cuts U.S. list price of Lantus®, its most-prescribed insulin, by 78% and caps out-of-pocket Lantus costs at $35 for all...

EDISON, N.J., March 16, 2023 (GLOBE NEWSWIRE) -- Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA), a clinical stage biopharmaceutical company focused on Artificial Intelligence (“AI”)-driven therapeutic drug development for the treatment of fibrotic diseases, including non-alcoholic steatohepatitis (“NASH”), hepatocellular carcinoma (“HCC”), and other chronic diseases, announces that its Chief Executive Officer, Robert Foster, PharmD, PhD, and its Senior Vice President for Clinical Pharmacology and Analytics, Patrick Mayo, PhD, will be presenting during a webinar entitled “How Artificial Intelligence is Changing Drug Discovery” on Thursday, March 23rd at 1:00 p.m. Eastern Time.

More here:
Hepion Pharmaceuticals to Participate in ACS-JPS Webinar on AI Drug Development

MINNEAPOLIS, March 16, 2023 (GLOBE NEWSWIRE) -- Panbela Therapeutics, Inc. (Nasdaq: PBLA), a clinical stage company developing disruptive therapeutics for the treatment of patients with urgent unmet medical needs, today provides a business update and reports financial results for the quarter and full year ended December 31, 2022. As previously announced, management is hosting earnings call today at 4:30 p.m. ET.

Continued here:
Panbela Provides Business Update and Reports Q4 and FY 2022 Financial Results